A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma

被引：27

作者：

Long, Mary C. ^{[1
]}

Bennetto-Hood, Chantelle ^{[1
]}

Acosta, Edward P. ^{[1
]}

机构：

[1] Univ Alabama Birmingham, Sch Med, Div Clin Pharmacol, Birmingham, AL 35294 USA

来源：

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2008年 / 867卷 / 02期

关键词：

HIV; integrase inhibitor; mass spectrometry; human; raltegravir;

D O I：

10.1016/j.jchromb.2008.03.022

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

This work describes an assay system that has been developed to quantify raltegravir concentrations in human plasma using a liquid-liquid extraction technique paired with HPLC separation and MS-MS detection. The dynamic range of this assay extends from 1 to 3000 ng/mL, with a coefficient of determination (r(2), mean +/- SD) of 0.9992 +/- 0.0002. The mean precision values for calibration standards ranged from 0.6% to 3.0%, while accuracy values were 96.5-104.3%. This procedure is an accurate, precise, and sensitive method for raltegravir quantitation and was successfully validated using external proficiency testing. (c) 2008 Elsevier B.V. All rights reserved.

引用

页码：165 / 171

页数：7

共 8 条

[1]

[Anonymous], 2007, AIDS Patient Care STDS, V21, P702

[2] Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial [J].

Grinsztejn, Beatriz ;

Nguyen, Bach-Yen ;

Katlama, Christine ;

Gatell, Jose M. ;

Lazzarin, Adriano ;

Vittecoq, Daniel ;

Gonzalez, Charles J. ;

Chen, Joshua ;

Harvey, Charlotte M. ;

Isaacs, Robin D. .

LANCET, 2007, 369 (9569) :1261-1269

[3]

IWAMOTO M, 2007, CLIN PHARM THER

[4] Metabolism and disposition in humans of raltegravir (MK-0518), an Anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme [J].

Kassahun, Kelem ;

McIntosh, Ian ;

Cui, Donghui ;

Hreniuk, David ;

Merschman, Shelia ;

Lasseter, Kenneth ;

Azrolan, Neal ;

Iwamoto, Marian ;

Wagner, John A. ;

Wenning, Larissa A. .

DRUG METABOLISM AND DISPOSITION, 2007, 35 (09) :1657-1663

[5] Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals [J].

Markowitz, Martin ;

Morales-Ramirez, Javier O. ;

Nguyen, Bach-Yen ;

Kovacs, Colin M. ;

Steigbigel, Roy T. ;

Cooper, David A. ;

Liporace, Ralph ;

Schwartz, Robert ;

Isaacs, Robin ;

Gilde, Lucinda R. ;

Penning, Larissa ;

Zhao, Jing ;

Teppler, Hedy .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (05) :509-515

[6] Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS [J].

Merschman, S. A. ;

Vallano, P. T. ;

Wenning, L. A. ;

Matuszewski, B. K. ;

Woolf, E. J. .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2007, 857 (01) :15-24

[7] In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediate [J].

Savarino, Andrea .

RETROVIROLOGY, 2007, 4

[8] Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry [J].

Taylor, PJ .

CLINICAL BIOCHEMISTRY, 2005, 38 (04) :328-334

← 1 →